• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The 8-deutero, 8-tritio and 8-halo-substituted derivatives of d-6-fluoro-spiro-[chroman-4,4'-imidazolidinel-2',5'-dione (sorbinil) have been prepared. These compounds all have the 4S-configuration and are of value in the field of medicinal chemistry as aldose reductose inhibitors for the control of chronic diabetic complications. The labeled 8-deutero and 8-tritio derivatives are useful in metabolism pharmacokinetic studies and in binding studies with the drug in animals and man. The 8-halo derivatives are useful as intermediates for the labeled forms of the drug, in addition to being potent aldose reductose inhibitors per se. Methods forthe preparation of these compounds are provided in some detail.
    公开号:SU1240362A3
    申请号:SU843732823
    申请日:1984-04-25
    公开日:1986-06-23
    发明作者:Сарджен Рейнхард
    申请人:Пфайзер Инк., (Фирма)；
    IPC主号:
    专利说明:

     cm
    This invention relates to a process for the preparation of hydantoin derivatives, namely deforming isomers of asymmetric spirohydantoins of the general formula
    where .X is deuterium, tritium or halogen which are aldose reductase inhibitors, have the ability to inhibit the accumulation of sorbitol in the lenses of the eye and the peripheral nerves of diabetic subjects, and can be used in the treatment of chronic diabetic complications.
    The labeled 8-deutero- and 8-tritium derivatives can be used in the study of pharmacokinetic and metabolism when changing drugs in animals and humans.
    The purpose of the invention is to create a method for obtaining new compounds with valuable pharmacological properties based on known methods.
    Example. 1. 2.00 g (0.00847 mol) of 45 6-ftpr-spiro- (chroman-4,4-imidazolidine) -2, 5-dione are placed in a reaction vessel, dissolved in 100 ml of glacial acetic acid at room temperature (). The reaction vessel was equipped with a glass purification apparatus containing an ethanol solution of aniline (10: 1 by volume) and a 10% aqueous solution of sodium hydroxide. A 10% solution of fluorine gas in nitrogen is then passed through the mixture for 60 minutes. After an additional 16 hours of flushing with nitrogen, the resulting reaction mixture is evaporated under vacuum to an oil, then triturated and then evaporated twice under vacuum with 100 ml of hexane. The foam thus obtained is triturated with ether to obtain a brown solid, which is recrystallized from a freshly prepared 10% aqueous solution of sodium bisulfate. The resulting product is chromatographed on an 8 Jorlax C-8 column of high pressure liquid chromatography using 85:16 v / v as eluent.

    20
    240362
    acetonitrile solution. The fractions were combined and evaporated in vacuo to give a residual liquid, which was later azeotroped with ethanol, then
    5 with ethyl acetate and, finally, cyclohexane to finally obtain the desired product as a white powder. Recrystallization from water gives 13 mg of pure 4S10 6,8-difluoro-spiro- (chroman-4,4-imidazolidine) -2,5-dione, etc. 198-200 s. The pure product is characterized by the data of mass spectroscopy and nuclear magnetic resonance in addition to elemental analysis. Mass spectrum: m / e 254 (P).
    PRI mme R 2. Through the solution containing. 1, 1 8 1 g (0.00465 mol) 4S-6-fluoro-spiro- (chroman-4,4-imidazole-dine) -2, 5 -dione dissolved in
    10 ml of dimethylformamide (dry sieve) containing traces of ferric chloride are gaseous at -40 ° C
    chlorine for 20 min. Receipt the solution is stirred at -20 ° C for -2.5 hours and then brought to room temperature (20 ° C) for 2 hours. Then 50 ml of water are carefully added, the reaction mixture is vigorously stirred overnight at room temperature (approximately 16 hours). Upon completion of this step, the reaction mixture is added to 100 ml of ethyl acetate and the aqueous phase is extracted with ethyl acetate (25 ml). The combined organic extracts are washed twice with brine and then dried over anhydrous magnesium sulphate. The filtered solvent is evaporated under reduced pressure and a golden yellow oil is obtained as residual liquid. The chromatographic oil is sprayed onto a 230-400 mesh silica gel column (4.5 x 15.0 cm) and eluted with ethyl acetate in a .30 ml fraction. Fraction number 7 con-C8Ntriyu.t c-colorless oil, which can be crystallized in a white solid (yield 0,251 g), so pl. 108-114 C. Fraction No. 8 is concentrated to a colorless oil, which is then triturated with petroleum ether to give 0.196 g (15.4%) of pure, 4S-6-fluoro-8-chloro-spiro- (chroman-4,4 -im - dazolidin) -2, -5-dione in the form of a white solid, etc. 99-102 s (decomposition). Fraction No. 9 is concentrated to a clear oil, which is then triturated with pentane to form a more crystalline solid.
    during which also contains pure
    48-6-fluoro-8-chloro-spiro- (chroman-4,4 - imidazolidine) -2, 5 g-dione., So pl. 100- (decomposition); until the pure product leaves this fraction fraction to 0.257 g (20, .2%). The pure product of fraction No. 8 is characterized by mass spectrometry and nuclear magnetic resonance data, as well as elemental analysis data. Mass-10 goes to the deuterization stage).
    spectrum: m / e. 272/270 (P).
    Calculated,%: C 47.75; H 3.16;
    N 10.13.
    С4, Hg CljFNjGj 1/3 Н О Found,%: С48.19; H 3.51;
    N 9.68.
    15
    PRIOR EMERF. 4. A solution containing 60 .mg (0.00022 mol) 48-6-f -8-chloro-spiro- (chroman-4,4-imidine) -2, 5 -dione (fraction No. 8, in Example 2), dissolve 4.0 ml of ethanol containing 0.5% triethylamine, treat with 10 catalyst 10% palladium at an angle and stir in an atmosphere t using an atmospheric hydrogenation autoclave (atmospheric pressure at room temperature ( for 18 h. Then the autoclave is desorbed for hydrogenation, the tritium is removed using a
    Example 3. B. A 35 ml round-bottomed vessel is placed in a solution containing 60 mg (0.00022 mol) of 45-6-fluoro-8-chloro-spiro- (xr man-4, V-imidazolidine) -2, 5 -dione (fraction 9 obtained in example 2) is dissolved in 4 ml of ethanol. Then 0.5 ml of triethylamine and 100 mg of catalyst — 10% palladium on carbon are added to this solution. The resulting mixture is then treated with a gaseous action (Dg) in an atmospheric autoclave for hydrogenation with stirring for 4 hours. After this time, the stirring is stopped and the reaction mixture is allowed to continue for overnight at room temperature (20 ° C) (approximately 16h) The contents are then removed from the autoclave for hydrogenation, filtered through celite to remove the catalyst and concentrated under vacuum to obtain a residual solid. yellow color. It is then distilled under high vacuum for 1 hour to obtain a more solid. This product is a crude 45-fluoro-8-deutepospiro- (chroman-4,4-imidazolidine) -. 2, 5-dione, which is chromatographed in the form of an ethyl acetate suspension on a silica gel column 230-400 mesh (5 ml in 10 ml pipette), eluted with 100% pure ethyl acetate, collecting 1.5 ml fractions. Fractions 5–9 were found to contain pure, product, they were combined and concentrated under vacuum, followed by distillation under high vacuum to remove excess ethnyl acetate, to give a white white substance. Re-precipitation from ethanol (diethyl ether gives pure 45-6-fluoro-8-deyto
    624
    spiro- (chroman-4,4 / -imidazolidine) - 2, so pl. 228-231 s. The pure product was characterized using mass spectroscopy, the data of which compared to a sample of pure 4S6-fluoro-c. Pyro (chroman-4,4 imidazolidine) -2, 5-dione show that 41% of the final product contains deuterium (t. E., binding of 41% H inter 5
    0
    0
    five
    50
    5th
    0
    PRIOR EMERF. 4. A solution containing 60 .mg (0.00022 mol) 48-6-fluoro-8-chloro-spiro- (chroman-4,4 -imidazolidine) -2, 5 -dione (fraction No. 8 obtained in Example 2) is dissolved in 4.0 ml of ethanol containing 0.5 MP triethylamine, treated with 100 mg of catalyst 10% palladium on carbon and stirred under tritium atmosphere using an atmospheric autoclave for g of hydrogenation (atmospheric pressure), at room temperature () for 18 hours. Then, they are desorbed from the autoclave for hydrogenation, the excess tritium is removed using azeotrope methanol, and the catalyst is reduced from the reaction mixture with.
    using filtering. The resulting filtrate is then concentrated under vacuum and the residue is redissolved in a mixture of -1.5 ml of methanol and 5.5 ml of benzene. At this one stage, the chromatographic thin layer analysis of TSHZ using 100% pure ethyl acetate as eluant shows the absence of: starting material. The above solution, containing crude 45-6-fluoro-9-tritium-spiro- (chroman-4,4-imidazolidine) -2, 5-dione, is then evaporated under vacuum and then re-dissolved in 0.5 ml of pure ethyl acetate and chromatographic on a 230-400 mesh / 5 ml silica gel column, in a 10 ml pipette, using 100% pure ethyl acetate as eluent. Fractions Nos. 6 and 7 containing a simple peak material (determined by the radio scan of those plates) are combined and evaporated under vacuum to obtain pure 43-6-fluoro-8-tritium-spiro- (chroman-4,4-imidazolidine) -2, 5-dione. . Radiochemical analysis showed that the product contains 34.6% tritium as compared with a genuine sample of the starting material (i.e. 34.6% H bonding occurs during the above mentioned reaction step),
    PRI me R 5. The transformation of 4S- 6,8-difluoro-spirb- (chroman-4,4 -imide 512403626
     zolidin) -2, 5 -dione to 48-6-fluoro-8-melt at a concentration to
    tritium-spiro (chroman-4,4-imidazoli-, to determine their ability to lower
    din) -2,5-dione occurs by inducing or suppressing enzyme activity by aldoluting nickel Raney in 5za medium, by the method of S. Hayina et al and potassium hydroxide using the improved method of K. Sestanj
    gaseous tritium. Cleaning chain-et al., In each case, applied
    product is achieved using the substrate is a particularly
    By using the same highly purified aldose reductase systems,
    liquid chromatography (HPLS) pressures obtained from a calf lens,
    previously used in example 1 so that the results obtained for each
    highlight pure starting material. Connections are expressed below in terms of
    This is a special way of appropriately inhibiting enzyme activity.
    The target product is obtained, namely (%) relative to a certain choice of 48-6-fluoro-8-tritium-spiro- (chroman-4,4 - 15 granular concentrated
    . imidazolidine) -2, 5 -dione, similar in. ():
    all ratios on the product of example 4. „
    Compound% suppression
    . , „At
    Example 6. The following asymmetric spiro-hydantoin of compound 20: the product of example 1: 74 examples 1 and 2, respectively, test. Product of Example 2 64
    权利要求:
    Claims (4)
    [1]
    1. METHOD FOR PRODUCING HYDANTOIN DERIVATIVES of the general formula where X is deuterium, tritium or halogen, characterized in that 4 S-6-fluoro-spiro (chroman-4,4 1- imide zolidine) -2 ', 5'-dione are treated gaseous fluorine or chlorine at a temperature of from (-20) to 20 ° C in an organic solvent with the release of compounds of the specified formula, where X is fluorine or chlorine, or with subsequent reduction of the obtained compound with deuterium or tritium over a skeletal Raney nickel catalyst or over a catalyst basis of noble metal.
    [2]
    2. The method according to claim 1, characterized in that as an organo; In the halogenation stage, glacial acetic acid or dimethylformamide is used as a solvent. ’§
    [3]
    3. The method according to claim 1, characterized in that at the stage of catalytic reduction, palladium on charcoal is used as the catalyst and the process is carried out in an environment in ethanol.
    [4]
    4. The method according to claim 1, with the same temperature and the fact that when reduced over a skeletal nickel Raney catalyst, the process is carried out in an environment of aqueous potassium hydroxide.
    1240362 AZ f
    1240362 '*
    类似技术:
    公开号 | 公开日 | 专利标题
    KR100400941B1|2003-12-24|Condensed six-ring compound and a process for producing the same
    SK283591B6|2003-10-07|Process to prepare tolterodine
    Pelletier et al.1981|Isolation and structure elucidation of the alkaloids of Delphinium glaucescens Rybd
    EP0340064A1|1989-11-02|Benzodiazepines, process and intermediates for their preparation and their use in therapy
    SU1745121A3|1992-06-30|Method of 3,5-dimethyl-4-methoxypyridine -2-methanol synthesis
    EP0924199B1|2006-05-10|Crystals of vitamin d derivatives and process for the preparation thereof
    US4649197A|1987-03-10|Sulfate of 5,6,7,8-tetrahydro-L-erythro-biopterin and process for preparing the same
    SU1240362A3|1986-06-23|Method of producing hydantoin derivatives
    US4345082A|1982-08-17|Process for the preparation of hydroxyamino-eburnane derivatives and octahydroindoloquinolizine intermediates
    RU2715720C2|2020-03-03|METHOD OF PRODUCING 17β-HYDROXY-DES-A-ANDROST-9,10-EN-5-ONE
    Allan et al.1986|Synthesis of Analogs of GABA. 15. Preparation and Resolution of Some Potent Cyclopentene and Cyclopentane Derivatives
    Dhanak et al.1987|Synthesis of [6]| pyridinophanes
    RU2448957C2|2012-04-27|Fluorinated catharantine derivatives, their obtaining and application as precursors of dimeric vinca alkaloids
    EP0285270B1|1992-06-03|A method for producing 1-propargyl-2,4-dioxoimidazolidine
    GB2036744A|1980-07-02|Eburnane derivatives
    DE2700234A1|1977-07-14|ORGANIC COMPOUNDS AND METHOD OF PREPARATION
    Compernolle et al.1997|The synthesis of ester and ketone analogues of 1-deoxynojirimycin and castanospermine
    SU576951A3|1977-10-15|Method of preparing leurosine derivatives or salts thereof
    KR950008970B1|1995-08-10|Process for preparing t'butyl ergoline derivatives
    SU1409122A3|1988-07-07|Method of producing vincubine
    HU186974B|1985-10-28|Process for the preparation of 3a,7a-trans-4-bracket-7,7-ethylendioxy-3-oxo-octyl-bracket closed-7abeta-methyl-perhydro-indan-1,5-dione
    JP2002234896A|2002-08-23|Cyathane derivative
    US5202443A|1993-04-13|Process for preparing 1-|-3-mercapto-methyl-1-oxopropyl)-l-proline
    CA1207780A|1986-07-15|2,6-dioxa-bicyclo-|-octan-7-yl-acetaldehydes
    JP3435692B2|2003-08-11|Sheatan derivative
    同族专利:
    公开号 | 公开日
    KR860000915B1|1986-07-18|
    EP0124327A3|1985-07-31|
    CA1226866A|1987-09-15|
    JPS59205384A|1984-11-20|
    NZ207959A|1987-04-30|
    ES531873A0|1986-06-01|
    IL71656D0|1984-07-31|
    CS250661B2|1987-05-14|
    FI841657A|1984-10-28|
    HU191755B|1987-04-28|
    YU43358B|1989-06-30|
    DK208284A|1984-10-28|
    DK208284D0|1984-04-26|
    US4474967A|1984-10-02|
    AU542142B2|1985-02-07|
    KR840008355A|1984-12-14|
    PL142759B1|1987-11-30|
    FI841657A0|1984-04-26|
    IL71656A|1987-10-20|
    ES8607312A1|1986-06-01|
    PT78476A|1984-05-01|
    NO841627L|1984-10-29|
    PT78476B|1986-08-28|
    AU2726384A|1984-11-01|
    EP0124327A2|1984-11-07|
    DD219772A5|1985-03-13|
    YU74184A|1986-10-31|
    PL247379A1|1985-03-26|
    ZA843091B|1985-12-24|
    HUT34197A|1985-02-28|
    GR81491B|1984-12-11|
    PH22869A|1989-01-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3821383A|1972-07-10|1974-06-28|Ayerst Mckenna & Harrison|Compositions for and a method of treating diabetic complications|
    US4117230A|1976-10-18|1978-09-26|Pfizer Inc.|Hydantoin derivatives as therapeutic agents|
    CA1088945A|1976-10-18|1980-11-04|Pfizer Limited|Hydantoin derivatives as therapeutic agents|
    US4130714A|1977-05-23|1978-12-19|Pfizer Inc.|Hydantoin therapeutic agents|
    US4248882A|1980-02-12|1981-02-03|Pfizer Inc.|Treating diabetes-associated complications with hydantoin amines|
    JPS6332793B2|1980-07-21|1988-07-01|Eisai Co Ltd|DE3565105D1|1984-08-20|1988-10-27|Pfizer|Process for the production as asymmetric hydantoins|
    US4841079A|1987-08-07|1989-06-20|Pfizer, Inc.|Process for the production of asymmetric hydantoins|
    US5059693A|1989-10-06|1991-10-22|Pfizer Inc.|Process for making 3-aroyl-2-oxindole-1-carboxamides|
    GB9317764D0|1993-08-26|1993-10-13|Pfizer Ltd|Therapeutic compound|
    EP1004307B1|1998-01-30|2002-09-04|R-Tech Ueno, Ltd.|Ophthalmic composition|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US06/488,947|US4474967A|1983-04-27|1983-04-27|8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione|
    [返回顶部]